Source: Bizjournals

Dyne: Dyne raises $233M in 19th Mass. IPO this year

Amid a parade of upsized biotech IPOs this year, a Waltham company working on drugs to treat muscle diseases made its debut with a $233 million fundraise today — more than double what it said it was hoping to bring in when it first filed its plans last month.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Joshua Brumm's photo - President & CEO of Dyne

President & CEO

Joshua Brumm

CEO Approval Rating

90/100

Dyne is a biotechnology company that develops and commercializes therapeutics for the treatment of genetic diseases. Read more